December 12, 2014
Track this case
Gregory M. Sleet
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.Additional or older documents may be available in Pacer.
Teva Pharmaceutical Industries Ltd. will be able to market a generic version of AstraZeneca’s diabetes drug Byetta by October 2017, according to a patent infringement settlement filed Thursday in Delaware federal court.
Already a subscriber? Click here to login